GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:000697914 | Breast | IDC | response to oxidative stress | 83/1434 | 446/18723 | 2.36e-14 | 7.06e-12 | 83 |
GO:190288214 | Breast | IDC | regulation of response to oxidative stress | 16/1434 | 98/18723 | 3.06e-03 | 2.60e-02 | 16 |
GO:000697924 | Breast | DCIS | response to oxidative stress | 82/1390 | 446/18723 | 1.22e-14 | 3.85e-12 | 82 |
GO:190288223 | Breast | DCIS | regulation of response to oxidative stress | 16/1390 | 98/18723 | 2.24e-03 | 2.05e-02 | 16 |
GO:00463953 | Liver | NAFLD | carboxylic acid catabolic process | 73/1882 | 236/18723 | 4.16e-19 | 1.22e-15 | 73 |
GO:00160544 | Liver | NAFLD | organic acid catabolic process | 73/1882 | 240/18723 | 1.20e-18 | 2.34e-15 | 73 |
GO:00442825 | Liver | NAFLD | small molecule catabolic process | 91/1882 | 376/18723 | 8.96e-16 | 1.31e-12 | 91 |
GO:00066316 | Liver | NAFLD | fatty acid metabolic process | 92/1882 | 390/18723 | 3.38e-15 | 3.29e-12 | 92 |
GO:00723295 | Liver | NAFLD | monocarboxylic acid catabolic process | 39/1882 | 122/18723 | 2.40e-11 | 8.77e-09 | 39 |
GO:00090626 | Liver | NAFLD | fatty acid catabolic process | 34/1882 | 100/18723 | 6.81e-11 | 1.99e-08 | 34 |
GO:00193956 | Liver | NAFLD | fatty acid oxidation | 33/1882 | 103/18723 | 7.58e-10 | 1.53e-07 | 33 |
GO:00442425 | Liver | NAFLD | cellular lipid catabolic process | 52/1882 | 214/18723 | 1.15e-09 | 2.17e-07 | 52 |
GO:00550883 | Liver | NAFLD | lipid homeostasis | 44/1882 | 167/18723 | 1.48e-09 | 2.54e-07 | 44 |
GO:00344405 | Liver | NAFLD | lipid oxidation | 33/1882 | 108/18723 | 2.96e-09 | 4.56e-07 | 33 |
GO:00302585 | Liver | NAFLD | lipid modification | 49/1882 | 212/18723 | 1.97e-08 | 2.17e-06 | 49 |
GO:00160426 | Liver | NAFLD | lipid catabolic process | 63/1882 | 320/18723 | 1.35e-07 | 1.02e-05 | 63 |
GO:00066356 | Liver | NAFLD | fatty acid beta-oxidation | 23/1882 | 74/18723 | 5.09e-07 | 3.07e-05 | 23 |
GO:00069797 | Liver | NAFLD | response to oxidative stress | 78/1882 | 446/18723 | 7.85e-07 | 4.29e-05 | 78 |
GO:0033540 | Liver | NAFLD | fatty acid beta-oxidation using acyl-CoA oxidase | 5/1882 | 12/18723 | 4.41e-03 | 3.57e-02 | 5 |
GO:000697922 | Liver | HCC | response to oxidative stress | 281/7958 | 446/18723 | 9.75e-19 | 1.24e-16 | 281 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
ACOX2 | SNV | Missense_Mutation | rs145060799 | c.449N>T | p.Thr150Met | p.T150M | Q99424 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-AX-A1CE-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unspecific | Paclitaxel | SD |
ACOX2 | SNV | Missense_Mutation | rs376964394 | c.1502C>T | p.Thr501Met | p.T501M | Q99424 | protein_coding | tolerated(0.1) | benign(0.046) | TCGA-B5-A11E-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ACOX2 | SNV | Missense_Mutation | novel | c.1607N>T | p.Thr536Ile | p.T536I | Q99424 | protein_coding | deleterious(0) | benign(0.296) | TCGA-B5-A5OC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Chemotherapy | cisplatin | SD |
ACOX2 | SNV | Missense_Mutation | | c.243G>T | p.Met81Ile | p.M81I | Q99424 | protein_coding | tolerated(0.41) | benign(0) | TCGA-BG-A0MQ-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACOX2 | SNV | Missense_Mutation | novel | c.256C>A | p.His86Asn | p.H86N | Q99424 | protein_coding | tolerated(0.27) | benign(0.017) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ACOX2 | SNV | Missense_Mutation | | c.961G>A | p.Val321Ile | p.V321I | Q99424 | protein_coding | tolerated(0.09) | benign(0.006) | TCGA-D1-A103-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACOX2 | SNV | Missense_Mutation | | c.1454N>A | p.Cys485Tyr | p.C485Y | Q99424 | protein_coding | deleterious(0.03) | possibly_damaging(0.635) | TCGA-D1-A167-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
ACOX2 | SNV | Missense_Mutation | | c.1826N>G | p.Tyr609Cys | p.Y609C | Q99424 | protein_coding | deleterious(0.03) | probably_damaging(0.926) | TCGA-D1-A17H-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
ACOX2 | SNV | Missense_Mutation | rs756752270 | c.1942N>T | p.Arg648Cys | p.R648C | Q99424 | protein_coding | deleterious(0) | probably_damaging(0.993) | TCGA-DF-A2KU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
ACOX2 | SNV | Missense_Mutation | novel | c.530N>G | p.Glu177Gly | p.E177G | Q99424 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD |